MY141249A - Pharmaceutical composition comprising an s1p receptor agonist - Google Patents

Pharmaceutical composition comprising an s1p receptor agonist

Info

Publication number
MY141249A
MY141249A MYPI20041275A MYPI20041275A MY141249A MY 141249 A MY141249 A MY 141249A MY PI20041275 A MYPI20041275 A MY PI20041275A MY PI20041275 A MYPI20041275 A MY PI20041275A MY 141249 A MY141249 A MY 141249A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
receptor agonist
oral administration
sugar alcohol
composition suitable
Prior art date
Application number
MYPI20041275A
Other languages
English (en)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Colleen Ruegger
Alan Edward Royce
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY141249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corp filed Critical Novartis Ag
Publication of MY141249A publication Critical patent/MY141249A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MYPI20041275A 2003-04-08 2004-04-07 Pharmaceutical composition comprising an s1p receptor agonist MY141249A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
MY141249A true MY141249A (en) 2010-03-31

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20041275A MY141249A (en) 2003-04-08 2004-04-07 Pharmaceutical composition comprising an s1p receptor agonist

Country Status (41)

Country Link
US (11) US20060275357A1 (en:Method)
EP (5) EP2319502A1 (en:Method)
JP (3) JP5495467B2 (en:Method)
KR (3) KR20110005320A (en:Method)
CN (2) CN1767819B (en:Method)
AR (3) AR043987A1 (en:Method)
AT (3) ATE414508T1 (en:Method)
AU (1) AU2004228929B2 (en:Method)
BE (2) BE1015972A5 (en:Method)
BR (1) BRPI0409250B8 (en:Method)
CA (2) CA2521325C (en:Method)
CL (2) CL2004000745A1 (en:Method)
CY (3) CY1110260T1 (en:Method)
DE (4) DE202004021680U1 (en:Method)
DK (2) DK1613288T3 (en:Method)
EC (1) ECSP056090A (en:Method)
ES (3) ES2320767T3 (en:Method)
FR (2) FR2854073B1 (en:Method)
GB (1) GB2400318B (en:Method)
GR (1) GR1005052B (en:Method)
HR (3) HRP20100600A2 (en:Method)
HU (2) HUE028247T2 (en:Method)
IL (3) IL170888A (en:Method)
IS (2) IS2682B (en:Method)
IT (1) ITMI20040682A1 (en:Method)
LU (1) LU91867I2 (en:Method)
MA (1) MA27729A1 (en:Method)
MX (1) MXPA05010860A (en:Method)
MY (1) MY141249A (en:Method)
NO (4) NO329332B1 (en:Method)
NZ (3) NZ542622A (en:Method)
PE (5) PE20130200A1 (en:Method)
PL (2) PL1613288T3 (en:Method)
PT (1) PT1613288E (en:Method)
RU (5) RU2358716C2 (en:Method)
SG (1) SG175449A1 (en:Method)
SI (2) SI2316431T1 (en:Method)
TN (1) TNSN05256A1 (en:Method)
TW (1) TWI332847B (en:Method)
WO (1) WO2004089341A1 (en:Method)
ZA (1) ZA200507394B (en:Method)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
SG165364A1 (en) * 2005-09-09 2010-10-28 Novartis Ag Treatment of autoimmune diseases
CN105237621A (zh) 2005-11-09 2016-01-13 欧尼斯治疗公司 用于酶抑制的化合物
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
SI2041158T1 (sl) 2006-06-19 2013-09-30 Onyx Therapeutics, Inc. Peptidni epoksiketoni za inhibicijo proteasomov
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
RU2487703C2 (ru) * 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
MY149356A (en) * 2007-03-29 2013-08-30 Daiichi Sankyo Co Ltd Pharmaceutical composition
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
EP2465492B1 (en) * 2007-10-12 2015-07-01 Novartis AG Compositions comprising sphingosine I phosphate (sip) receptor modulators
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
US8785484B2 (en) 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
ES2676288T3 (es) * 2008-06-20 2018-07-18 Merck Patent Gmbh Matriz de comprimidos directamente compresible y rápidamente desintegrable
CN102076335A (zh) 2008-06-20 2011-05-25 诺瓦提斯公司 用于治疗多发性硬化的儿科组合物
WO2010025796A1 (en) * 2008-09-04 2010-03-11 Cargill Incorporated Tabletting of ervthritol
EP2796134B1 (en) 2008-10-21 2016-12-07 Onyx Therapeutics, Inc. Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
US8530522B2 (en) * 2008-11-11 2013-09-10 Novartis Ag Organic compounds
WO2010055027A2 (en) 2008-11-11 2010-05-20 Novartis Ag Organic compounds
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
ES2605034T3 (es) * 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited Composición farmacéutica con solubilidad mejorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
ES2560955T3 (es) 2010-03-19 2016-02-23 Daiichi Sankyo Company, Limited Cristal de derivado de diamina y procedimiento de producción del mismo
HUE031059T2 (en) 2010-03-19 2017-06-28 Daiichi Sankyo Co Ltd Procedure for improving anticoagulant administration
WO2011131368A2 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
JP5780657B2 (ja) 2010-07-02 2015-09-16 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
EP2661261B1 (en) 2011-01-07 2019-07-31 Novartis AG Immunosuppressant formulations
PT2665471T (pt) 2011-01-19 2018-03-21 Pathologica Llc Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
EP3831372A1 (en) 2013-01-08 2021-06-09 Pathologica LLC Mitoguazone for preventing the relapse or the progression of multiple sclerosis
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
TW202245741A (zh) * 2021-01-28 2022-12-01 法商普萊歐塞拉公司 使用s1p受體調節劑之治療方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
PT778263E (pt) 1994-08-22 2002-06-28 Mitsubishi Pharma Corp Composto de benzeno e sua utilizacao farmaceutica
RU2156127C2 (ru) 1995-12-28 2000-09-20 Еситоми Фармасьютикал Индустриз, Лтд. Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
BR9811453A (pt) * 1997-02-27 2000-09-12 Yoshitomi Pharmaceutical Composição farmacêutica
NZ500713A (en) * 1997-04-04 2000-07-28 Yoshitomi Pharmaceutical 2-aminopropane-1,3-diol compounds and medicinal use thereof
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
BR0112484A (pt) 2000-07-13 2003-09-23 Sankyo Co Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
DK1431284T3 (da) 2001-09-27 2008-02-18 Kyorin Seiyaku Kk Diarylsulfidderivat, additionssalt deraf samt immunundertrykkende middel
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym

Also Published As

Publication number Publication date
US20130108675A1 (en) 2013-05-02
FR11C0036I2 (fr) 2023-12-29
HRP20100600A2 (hr) 2011-03-31
ITMI20040682A1 (it) 2004-07-06
ATE414508T1 (de) 2008-12-15
HRP20100601B1 (hr) 2016-12-02
NZ542622A (en) 2009-01-31
PE20131352A1 (es) 2013-11-14
HRP20050886A2 (en) 2006-11-30
AU2004228929A1 (en) 2004-10-21
TWI332847B (en) 2010-11-11
AT501681A1 (de) 2006-10-15
FR2854073A1 (fr) 2004-10-29
US20140011885A1 (en) 2014-01-09
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
CN101797241B (zh) 2013-03-27
IL197578A (en) 2015-10-29
DE102004016947A1 (de) 2004-10-21
US20080311188A1 (en) 2008-12-18
ECSP056090A (es) 2006-03-01
NO334116B1 (no) 2013-12-16
EP1613288B1 (en) 2008-11-19
DK2316431T3 (en) 2016-01-11
PE20050396A1 (es) 2005-07-05
PE20130200A1 (es) 2013-03-09
PE20150676A1 (es) 2015-05-17
KR20120101148A (ko) 2012-09-12
US20110105620A1 (en) 2011-05-05
TNSN05256A1 (en) 2007-07-10
CY1110260T1 (el) 2014-04-09
US20200237690A1 (en) 2020-07-30
AT501681B1 (de) 2012-04-15
HRP20050886B1 (en) 2011-01-31
JP2004307506A (ja) 2004-11-04
MA27729A1 (fr) 2006-01-02
LU91867I2 (fr) 2011-11-08
IS8885A (is) 2010-02-25
EP1613288A1 (en) 2006-01-11
RU2358716C2 (ru) 2009-06-20
RU2475237C2 (ru) 2013-02-20
CN101797241A (zh) 2010-08-11
LU91867I9 (en:Method) 2019-01-03
SI1613288T1 (sl) 2009-04-30
AU2004228929B2 (en) 2008-02-07
US20190175527A1 (en) 2019-06-13
GR20040100121A (el) 2004-12-17
AT504853A2 (de) 2008-08-15
RU2010147000A (ru) 2012-08-10
KR20110005320A (ko) 2011-01-17
EP2008650A2 (en) 2008-12-31
HK1155647A1 (en) 2012-05-25
SI2316431T1 (sl) 2016-04-29
ES2320767T3 (es) 2009-05-28
US20220031609A1 (en) 2022-02-03
JP5495467B2 (ja) 2014-05-21
CA2521325C (en) 2010-09-14
CY2011013I2 (el) 2014-04-09
TW200503784A (en) 2005-02-01
PL1613288T3 (pl) 2009-07-31
DE202004021680U1 (de) 2010-04-22
PE20090743A1 (es) 2009-07-17
DE122011100047I1 (de) 2011-12-15
SG175449A1 (en) 2011-11-28
HRP20100601A2 (hr) 2011-03-31
ES2228282A1 (es) 2005-04-01
NO2011016I2 (no) 2012-08-27
HUS1100016I1 (hu) 2016-08-29
CY1117071T1 (el) 2017-04-05
DE602004017847D1 (de) 2009-01-02
ES2228282B1 (es) 2006-02-16
NO20100250L (no) 2006-01-09
CA2707750A1 (en) 2004-10-21
GB2400318B (en) 2005-08-10
CA2521325A1 (en) 2004-10-21
KR20050121712A (ko) 2005-12-27
NO335120B1 (no) 2014-09-22
DK1613288T3 (da) 2009-03-23
AR078781A2 (es) 2011-11-30
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
BRPI0409250A (pt) 2006-03-28
IS2682B (is) 2010-10-15
IL242037A0 (en) 2015-11-30
NO2011016I1 (no) 2011-09-19
CY2011013I1 (el) 2014-04-09
NZ586280A (en) 2011-12-22
IL170888A (en) 2010-06-16
EP2316431B1 (en) 2015-09-30
US20170290787A1 (en) 2017-10-12
NO329332B1 (no) 2010-09-27
RU2010146697A (ru) 2012-05-27
EP2008650A3 (en) 2011-04-27
RU2475236C2 (ru) 2013-02-20
NO20055231D0 (no) 2005-11-07
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
US8324283B2 (en) 2012-12-04
US20090203798A1 (en) 2009-08-13
GB0407819D0 (en) 2004-05-12
IS8114A (is) 2005-11-01
EP2319502A1 (en) 2011-05-11
PT1613288E (pt) 2009-02-25
BE2011C030I2 (en:Method) 2023-03-07
KR101367574B1 (ko) 2014-02-25
FR11C0036I1 (fr) 2011-10-14
HUE028247T2 (en) 2016-12-28
GB2400318A (en) 2004-10-13
AR078782A2 (es) 2011-11-30
RU2005134173A (ru) 2006-09-10
CL2004000745A1 (es) 2005-02-11
JP5543298B2 (ja) 2014-07-09
HK1091114A1 (en) 2007-01-12
IL197578A0 (en) 2011-07-31
JP2013177404A (ja) 2013-09-09
AR043987A1 (es) 2005-08-17
US20140255497A1 (en) 2014-09-11
MXPA05010860A (es) 2006-05-25
IE20040246A1 (en) 2004-12-15
BRPI0409250B8 (pt) 2022-01-18
BRPI0409250B1 (pt) 2017-07-11
EP2769713A1 (en) 2014-08-27
NO20131287L (no) 2006-01-09
RU2009105403A (ru) 2010-08-27
RU2012148593A (ru) 2014-05-20
CN1767819A (zh) 2006-05-03
ZA200507394B (en) 2007-03-28
US20060275357A1 (en) 2006-12-07
ES2556947T3 (es) 2016-01-21
NZ592339A (en) 2012-09-28
CN1767819B (zh) 2010-07-28
FR2854073B1 (fr) 2008-03-14
GR1005052B (el) 2005-11-30
WO2004089341A1 (en) 2004-10-21
JP2011006461A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
MY141249A (en) Pharmaceutical composition comprising an s1p receptor agonist
AU2002350584A1 (en) Dopamine agonist formulations for enhanced central nervous system delivery
MXPA03005257A (es) Composiciones frarmaceuticas de un agonista del receptor de nmda.
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
WO2004032866A3 (en) Therapeutic formulations
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
IL161834A0 (en) Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
WO2004012722A3 (en) Bicifadine formulation
NO20064808L (no) Orale matrixformuleringer med licarbazepin
AU2003245033A1 (en) An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
IL179014A0 (en) Film-shaped medicament for oral administration, containing estriol
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
AU2003258578A1 (en) Filling device for capsules, in particular medicament capsules
HK1071685B (en) Pharmaceutical composition comprising an s1p receptor agonist
AU2003254672A1 (en) Dual-spike release formulation for oral drug delivery
HK1085648A (en) Methods for making pharmaceutical dosage forms containing active cushioning components